Division of Cardiovascular Medicine, Department of Medicine, Diabetes and Obesity Center, Institute of Molecular Cardiology, University of Louisville, 580 South Preston Street-321F, Delia Baxter Building-321F, Louisville, KY, 40202, USA.
Division of Cardiovascular Medicine, Department of Medicine, Cardiovascular Innovation Institute, University of Louisville, Louisville, KY, USA.
Basic Res Cardiol. 2019 May 31;114(4):28. doi: 10.1007/s00395-019-0737-y.
Several post-translational modifications figure prominently in ventricular remodeling. The beta-O-linkage of N-acetylglucosamine (O-GlcNAc) to proteins has emerged as an important signal in the cardiovascular system. Although there are limited insights about the regulation of the biosynthetic pathway that gives rise to the O-GlcNAc post-translational modification, much remains to be elucidated regarding the enzymes, such as O-GlcNAc transferase (OGT) and O-GlcNAcase (OGA), which regulate the presence/absence of O-GlcNAcylation. Recently, we showed that the transcription factor, E2F1, could negatively regulate OGT and OGA expression in vitro. The present study sought to determine whether E2f1 deletion would improve post-infarct ventricular function by de-repressing expression of OGT and OGA. Male and female mice were subjected to non-reperfused myocardial infarction (MI) and followed for 1 or 4 week. MI significantly increased E2F1 expression. Deletion of E2f1 alone was not sufficient to alter OGT or OGA expression in a naïve setting. Cardiac dysfunction was significantly attenuated at 1-week post-MI in E2f1-ablated mice. During chronic heart failure, E2f1 deletion also attenuated cardiac dysfunction. Despite the improvement in function, OGT and OGA expression was not normalized and protein O-GlcNAcyltion was not changed at 1-week post-MI. OGA expression was significantly upregulated at 4-week post-MI but overall protein O-GlcNAcylation was not changed. As an alternative explanation, we also performed guided transcriptional profiling of predicted targets of E2F1, which indicated potential differences in cardiac metabolism, angiogenesis, and apoptosis. E2f1 ablation increased heart size and preserved remote zone capillary density at 1-week post-MI. During chronic heart failure, cardiomyocytes in the remote zone of E2f1-deleted hearts were larger than wildtype. These data indicate that, overall, E2f1 exerts a deleterious effect on ventricular remodeling. Thus, E2f1 deletion improves ventricular remodeling with limited impact on enzymes regulating O-GlcNAcylation.
几种翻译后修饰在心室重构中起着重要作用。β-O-连接的 N-乙酰葡萄糖胺(O-GlcNAc)与蛋白质的连接已成为心血管系统中的一个重要信号。尽管对于产生 O-GlcNAc 翻译后修饰的生物合成途径的调控有有限的了解,但对于调节 O-GlcNAc 酰化存在/不存在的酶,如 O-GlcNAc 转移酶(OGT)和 O-GlcNAcase(OGA),仍有许多需要阐明。最近,我们表明转录因子 E2F1 可以在体外负调节 OGT 和 OGA 的表达。本研究旨在确定 E2f1 缺失是否通过解除 OGT 和 OGA 的表达抑制来改善心肌梗死后的心室功能。雄性和雌性小鼠接受非再灌注性心肌梗死(MI),并随访 1 或 4 周。MI 显著增加了 E2F1 的表达。在没有干预的情况下,E2f1 的缺失本身不足以改变 OGT 或 OGA 的表达。E2f1 缺失的小鼠在心肌梗死后 1 周时心脏功能显著减弱。在慢性心力衰竭期间,E2f1 缺失也减弱了心脏功能障碍。尽管功能得到改善,但 OGT 和 OGA 的表达没有恢复正常,心肌梗死后 1 周时蛋白质 O-GlcNAcylation 没有改变。OGA 表达在心肌梗死后 4 周时显著上调,但整体蛋白质 O-GlcNAcylation 没有改变。作为另一种解释,我们还对 E2F1 的预测靶点进行了有针对性的转录谱分析,这表明心脏代谢、血管生成和细胞凋亡存在潜在差异。E2f1 缺失在心肌梗死后 1 周时增加了心脏大小并保留了远程区毛细血管密度。在慢性心力衰竭期间,E2f1 缺失的心脏的远程区的心肌细胞比野生型的更大。这些数据表明,总的来说,E2f1 对心室重构有有害影响。因此,E2f1 缺失改善了心室重构,对调节 O-GlcNAc 酰化的酶影响有限。